NEVRO CORP's ticker is NVRO and the CUSIP is 64157F103. A total of 152 filers reported holding NEVRO CORP in Q2 2024. The put-call ratio across all filers is 35.02 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2024 | $9,150,888 | +29.1% | 633,718 | +92.3% | 0.08% | +9.1% |
| Q4 2023 | $7,090,367 | +3.5% | 329,478 | -7.5% | 0.08% | -3.8% |
| Q3 2023 | $6,847,798 | +56.2% | 356,285 | +106.6% | 0.08% | +53.8% |
| Q2 2023 | $4,384,391 | -67.1% | 172,478 | -53.2% | 0.05% | -71.3% |
| Q1 2023 | $13,325,107 | +5.7% | 368,606 | +15.8% | 0.18% | +7.1% |
| Q4 2022 | $12,607,214 | -20.1% | 318,364 | -6.0% | 0.17% | -23.5% |
| Q3 2022 | $15,788,000 | -27.0% | 338,790 | -31.4% | 0.22% | -33.6% |
| Q2 2022 | $21,641,000 | +8.1% | 493,741 | +78.3% | 0.33% | +2.5% |
| Q1 2022 | $20,027,000 | +149.5% | 276,881 | +179.7% | 0.32% | +182.6% |
| Q4 2021 | $8,026,000 | -57.9% | 99,005 | -39.6% | 0.12% | -63.0% |
| Q3 2021 | $19,068,000 | +3010.6% | 163,842 | +4329.4% | 0.31% | +2727.3% |
| Q2 2021 | $613,000 | -92.5% | 3,699 | -94.7% | 0.01% | -96.7% |
| Q4 2019 | $8,138,000 | – | 69,233 | – | 0.33% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Consonance Capital Management LP | 1,446,333 | $82,441,000 | 4.44% |
| Asymmetry Capital Management, L.P. | 31,379 | $1,789,000 | 1.65% |
| TIRSCHWELL & LOEWY INC | 194,470 | $11,085,000 | 1.38% |
| ZEVENBERGEN CAPITAL INVESTMENTS LLC | 673,480 | $38,388,000 | 1.22% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 525,040 | $29,927,000 | 1.07% |
| Orbimed Advisors | 1,357,691 | $77,388,000 | 0.93% |
| Sio Capital Management, LLC | 45,091 | $2,570,000 | 0.88% |
| PURA VIDA INVESTMENTS, LLC | 60,000 | $3,420,000 | 0.72% |
| SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC | 159,800 | $9,109,000 | 0.62% |
| Endurant Capital Management LP | 24,171 | $1,378,000 | 0.61% |